Skip to main content
    V

    Vera Therapeutics Inc (VERA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $28.57
    +1.83 (+6.84%)

    Market Cap: $1.93B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    32%(7/22)
    Avg Surprise
    -34.46%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.61
    Range$-1.80 - $-1.39
    8 analysts
    EPS Revisions
    2
    0
    7d
    2
    5
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.54-4.5%
    60d ago$-1.54-4.5%
    30d ago$-1.64+1.9%
    7d ago$-1.62+0.2%
    Current$-1.61
    Revenue Consensus
    $4M
    Range$0 - $9M
    12 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.68
    Range$-2.65 - $-1.19
    9 analysts
    Revenue Consensus
    $20M
    Range$9M - $47M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.68---
    Sep 26EST
    		-$-1.61---
    Jun 26
    Reported Aug 10
    		$-1.52$-1.60+5.00%Beat-26.7%
    Mar 26
    Reported May 7
    		$-1.69$-1.37-23.36%Miss-108.6%
    Dec 25
    Reported Feb 26
    		$-1.39$-1.34-3.73%Miss-93.1%
    Sep 25
    Reported Nov 5
    		$-1.26$-1.20-5.00%Miss-48.2%
    Jun 25
    Reported Aug 5
    		$-1.20$-0.62-93.55%Miss-93.5%
    Mar 25
    Reported May 6
    		$-0.81$-0.78-3.85%Miss-44.6%
    Dec 24
    Reported Feb 26
    		$-0.72$-0.81+11.11%Beat-24.1%
    Sep 24
    Reported Nov 7
    		$-0.85$-0.62-37.10%Miss-88.9%
    Jun 24
    Reported Aug 8
    		$-0.62$-0.54-14.81%Miss-34.8%
    Mar 24
    Reported May 9
    		$-0.56$-0.53-5.66%Miss+30.0%
    Dec 23
    Reported Mar 20
    		$-0.58$-0.51-13.73%Miss+50.8%
    Sep 23
    Reported Nov 9
    		$-0.45$-0.54+16.67%Beat+50.5%
    Jun 23
    Reported Aug 10
    		$-0.46$-0.74+37.84%Beat+16.4%
    Mar 23
    Reported May 11
    		$-0.80$-0.45-77.78%Miss-12.7%
    Dec 22
    Reported Mar 28
    		$-1.18$-0.90-31.11%Miss-49.4%
    Sep 22
    Reported Nov 9
    		$-0.91$-0.90-1.11%Miss-152.8%
    Jun 22
    Reported Aug 10
    		$-0.55$-0.78+29.49%Beat-66.7%
    Mar 22
    Reported May 16
    		$-0.71$-0.64-10.94%Miss+94.2%
    Dec 21
    Reported Mar 24
    		$-0.79$-0.46-71.74%Miss+60.8%
    Sep 21
    Reported Nov 10
    		$-0.36$-0.59+38.98%Beat-71.8%
    Jun 21
    Reported Aug 16
    		$-0.33$-0.45+26.67%Beat-94.8%
    Mar 21
    Reported Apr 23
    		$-12.23$-1.94-530.41%Miss-10415.9%
    Dec 20
    Reported Dec 31
    		$-2.02N/AN/ABeat-
    Sep 20
    Reported Sep 30
    		$-0.21N/AN/ABeat-
    Jun 20
    Reported Jun 30
    		$-0.17N/AN/ABeat-
    Mar 20
    Reported Jun 29
    		$-0.12N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-4.88EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-91.70%ROIC-68.26%
    Financial Health
    Debt/Equity0.18xInterest Coverage-55.38x
    Current Ratio10.92xQuick Ratio10.92x
    Trading Statistics
    Beta1.05Avg Volume2.10M
    52-Week High$56.0552-Week Low$23.05

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$28.93
    SMA 20$31.05
    SMA 50$32.38
    SMA 200$37.99
    EMA 10$28.97
    EMA 20$30.34
    EMA 50$32.31
    EMA 200$34.76

    MACD

    Line: -1.59Signal: -1.24Hist: -0.35

    ADX

    ADX: 18.6+DI: 18.8-DI: 27.8

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down96.0
    PSAR$30.50

    Bollinger Bands

    Upper Band$36.18
    Lower Band$25.91
    %B Position3307%(Upper)
    Band Width0.26

    RSI (14-Day)

    Neutral
    39.7

    Momentum Oscillators

    Stoch %K12.9
    Stoch %D7.9
    Williams %R-69.6
    ROC (10d)-7.8%
    Momentum-2.42
    CCI (20d)-89.6
    MFI (14d)36.0

    Volatility Measures

    ATR (14d)$1.76(6.2%)
    StdDev (20d)2.57
    Hist Vol58.0%(High)

    Volume Flow

    VWAP$28.17
    OBV-6.9M
    AD Line12.5M
    CMF (20d)-0.018

    Volume Metrics

    Avg Vol (20d)1.9M
    Vol Ratio0.8x
    VWMA (20d)$31.06

    Pivot Points

    R3$28.36
    R2$27.89
    R1$27.32
    Pivot Point$26.84
    S1$26.27
    S2$25.80
    S3$25.23

    Advanced Oscillators

    TSI-25.44
    Ultimate Osc48.4
    KST-125.42

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0$-1,127,000$0$0$0N/A$0$0$0$-635,000$0
    Gross Profit$0$0$1.13M$0$0$0N/A$0$0$0$635,000$0
    Operating Expenses$112.49M$125.13M$94.21M$83.93M$80.14M$57.19M$48.91M$49.80M$37.34M$31.11M$27.03M$21.76M
    R&D$60.08M$86.01M$59.31M$56.47M$58.20M$41.28M$33.35M$40.31M$29.31M$23.20M$20.79M$16.10M
    SG&A$52.41M$39.12M$34.90M$27.46M$21.95M$15.92M$15.57M$9.49M$8.03M$7.91M$6.24M$5.66M
    Operating Income$-112,490,000$-125,132,000$-94,206,000$-83,932,000$-80,141,000$-57,194,000$-48,914,000$-49,801,000$-37,343,000$-31,112,000$-27,028,000$-21,756,000
    Interest Income$5.35M$6.36M$5.52M$5.74M$6.32M$6.91M$6.66M$4.76M$5.10M$4.19M$1.96M$2.16M
    Interest Expense$1.85M$1.82M$1.91M$1.96M$1.87M$1.79M$1.87M$1.94M$1.91M$1.91M$1.05M$943,000
    Income Before Tax$-109,473,000$-121,032,000$-91,096,000$-80,293,000$-76,531,000$-51,694,000$-43,424,000$-46,632,000$-33,708,000$-28,383,000$-25,654,000$-20,104,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-109,473,000$-121,032,000$-91,097,000$-80,293,000$-76,531,000$-51,694,000$-43,425,000$-46,632,000$-33,708,000$-28,383,000$-25,655,000$-20,104,000
    EBITDA$-113,293,000$-125,628,000$-95,045,000$-84,548,000$-82,592,000$-59,033,000$-50,009,000$-51,657,000$-39,494,000$-32,132,000$-27,725,000$-24,402,000
    EBIT$-112,973,000$-125,564,000$-94,708,000$-84,069,000$-80,977,000$-56,808,000$-48,215,000$-49,457,000$-36,900,000$-30,663,000$-26,558,000$-21,319,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VERA

    News

    Five new hires at Vera Therapeutics received share options and awards that vest over four years.

    Vera Therapeutics granted inducement awards consisting of stock options for 16,700 Class A shares and restricted stock units (RSUs) for 8,350 Class A shares to five new employees on September 29, 2026. These awards...

    Stock Titan•10/3/26•Neutral

    Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Vera Therapeutics announced inducement grants consisting of non-qualified stock options and restricted stock units to five new employees under its Inducement Plan. These awards, approved by the Compensation Committee...

    GlobeNewswire•10/3/26•Somewhat-Bullish

    Vera Therapeutics (NASDAQ: VERA) CEO exercises options and sells shares under preset trading plan

    Vera Therapeutics' President and CEO, Marshall Fordyce, exercised stock options for 18,500 shares of Class A Common Stock at an exercise price of $2.8968 per share on September 15, 2026. Simultaneously...

    Stock Titan•9/17/26•Neutral

    Vera Therapeutics CEO Marshall Fordyce Executes 18,500 Share Sale Under 10b5-1 Trading Plan

    Vera Therapeutics CEO Marshall Fordyce exercised stock options and subsequently sold 18,500 shares of Class A Common Stock on September 2, 2026...

    Kalkine Media•9/4/26•Neutral

    What Vera Therapeutics (VERA)'s Widening Losses and Cash Burn Mean For Shareholders

    Vera Therapeutics (VERA) reported a significant widening of net losses in Q2 2026 and the first half of 2026, reaching US$109.47 million and US$230.51 million respectively...

    Sahm•8/19/26•Bearish

    VERA Valuation and Fair Value

    P/E
    -4.9x
    P/B
    5.0x
    See GNG's fair value

    VERA Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROIC
    -68.3%
    ROE
    -91.7%

    VERA Competitors

    CompanyTicker
    Inspire Medical Systems IncINSP
    LeMaitre Vascular IncLMAT
    Recursion Pharmaceuticals IncRXRX
    BioLife Solutions IncBLFS
    Butterfly Network IncBFLY
    Schrodinger IncSDGR
    Fortrea Holdings Inc.FTRE
    UroGen Pharma LtdURGN

    Sector: Healthcare

    VERA Analyst Ratings

    Consensus
    Buy
    Analysts
    14
    Strong Buy
    1
    Buy
    12
    Hold
    1
    Sell
    0
    Strong Sell
    0

    VERA Bull Case vs Bear Case

    Bull case

    • 92.9% of VERA's analyst ratings are Buy or Strong Buy.

    Bear case

    • VERA beat EPS estimates in 25.0% of its last 8 reported quarters.

    VERA Earnings: Beat Rate and Next Report

    Beat rate
    2 of 8 quarters (25.0%)
    Average surprise
    -18.8%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.61
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 5 down

    Frequently Asked Questions About VERA

    Does VERA pay dividends?

    Vera Therapeutics Inc (VERA) does not currently pay a regular dividend.

    What is VERA's market cap?

    Vera Therapeutics Inc (VERA) has a market capitalization of $1.93B with a current stock price of $28.57.

    Related stocks

    Sector: Healthcare

    All stocks starting with V

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In